Androgens play a central role in prostate cancer pathogenesis, and hence most of the patients respond to androgen deprivation therapies. However, patients tend to relapse with aggressive prostate cancer, which has bee...Androgens play a central role in prostate cancer pathogenesis, and hence most of the patients respond to androgen deprivation therapies. However, patients tend to relapse with aggressive prostate cancer, which has been termed as hormone refractory. To identify the proteins that mediate progression to the hormone-refractory state, we used protein-chip technology for mass profiling of patients＇ sera. This study included 16 patients with metastatic hormone-refractory prostate cancer who were initially treated with androgen deprivation therapy. Serum samples were collected from each patient at five time points： point A, pre-treatment; point B, at the nadir of the prostate- specific antigen （PSA） level; point C, PSA failure; point D, the early hormone-refractory phase; and point E, the late hormone-refractory phase. Using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, we performed protein mass profiling of the patients＇ sera and identified a 6 640-Da peak that increased with disease progression. Target proteins were partially purified, and by amino acid sequencing the peak was identified as a fragment of apolipoprotein C-I （ApoC-I）. Serum ApoC-I protein levels increased with disease progression. On immunohistochemical analysis, the ApoC-i protein was found localized to the cytoplasm of the hormone-refractory cancer cells. In this study, we showed an increase in serum ApoC-I protein levels in prostate cancer patients during their progression to the hormone-refractory state, which suggests that ApoC-I protein is related to progression of prostate cancer. However, as the exact role of ApoC-I in prostate cancer pathogenesis is unclear, further research is required.展开更多
Background Endometriosis is a common gynecological disease. This study aimed to screen proteins that were expressed differently in patients with endometriosis versus normal controls using proteomic techniques, surface...Background Endometriosis is a common gynecological disease. This study aimed to screen proteins that were expressed differently in patients with endometriosis versus normal controls using proteomic techniques, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry （SELDI-TOF-MS）.Methods Protein chip SELDI-TOF-MS combines the advantages of microarray and mass spectrometry, and can screen latent markers in sera of patients with endometriosis. Serum samples from patients and normal volunteers were analyzed by SELDI-TOF-MS. Results After comparing the serum protein spectra of 36 patients with 24 normal controls, 24 differently expressed potential biomarkers （P 〈0.01） were identified. Using Biomarker Pattern software, we established a tree model of the 60 serum protein spectra. When using the three bJomarkers to classify the samples, the sensitivity for diagnosing endometriosis was 91.7%, specificity was 95.8%, and coincidence rate was 93.3%. Then we used serum samples from 12 patients and 8 normal controls to validate the tree model and report the sensitivity for diagnosing endometriosis was 91.7%, specificity was 75%, and coincidence rate was 85%. Conclusions SELDI-TOF-MS may be a useful tool in high-risk population screening for endometriosis. The identification and application of the biomarkers need to further study.展开更多
AIM:To investigate the relationship between urinary peptide changes and Helicobacter pylori(H.pylori) infection using urinary peptidome profiling.METHODS:The study was performed in volunteers(n = 137) who gave informe...AIM:To investigate the relationship between urinary peptide changes and Helicobacter pylori(H.pylori) infection using urinary peptidome profiling.METHODS:The study was performed in volunteers(n = 137) who gave informed consent.Urinary peptides were enriched by magnetic beads based weak cation exchange chromatography and spectrums acquired by matrix-assisted laser desorption/ionization time-of-flight(MALDI-TOF) mass spectrometry(MS).ClinProTools bioinformatics software was used for statistical analysis and the recognition of peptide patterns.The marker peptides were identified by LTQ Obitrap XL tandem MS.RESULTS:Approximately 50 proteins or peptides which loaded onto the magnetic beads were detected by MALDI-TOF MS.By optimizing the parameters of the model,the Genetic Algorithm model had good recognition capability(97%) and positive predictive value(94%).Based on the model,2 markers with molecular masses of 6788 and 1912 Da were found that differentiated between H.pylori positive and negative volunteers.The m/z 1912 sequence was parsed as SKQFTSSTSYNRGDSTF.The peptide was identified as isoform 1 of the fibrinogen α chain precursor,whose concentration in urine was markedly higher in H.pylori infected volunteers than in H.pylori non-infected ones.CONCLUSION:The appearance of urinary fibrinogen degradation products is caused by an active H.pyloriinduced process.展开更多
BACKGROUND:It has been pointed out that only low-dose arsenic trioxide(ATO)presents therapeutic benefits outweighing the toxic side effects.Low-dose ATO can effectively alleviate acute promyelocytic leukemia(APL). How...BACKGROUND:It has been pointed out that only low-dose arsenic trioxide(ATO)presents therapeutic benefits outweighing the toxic side effects.Low-dose ATO can effectively alleviate acute promyelocytic leukemia(APL). However,it is quite challenging in treating solid tumors. The purpose of this study was to investigate the effect of ATO at low concentrations on the metastatic potential of mouse hepatoma H22 cells and the anti-metastatic mechanism of ATO. METHODS:The metastatic potential of H22 cells was evaluated by adhesion,migration and invasion assays after exposure to a low dose of ATO in vitro.The mouse lung metastatic model induced by injection of H22 cells via the tail vein was adopted for the evaluation of metastatic potential. Different proteins in the lysate of H22 cells exposed to ATO at different concentrations were investigated by surface- enhanced laser desorption and ionization time-of-flight mass spectrometry(SELDI-TOF-MS).Finally,Western blotting analyses were made to detect the expression pattern of MMP-2 and nm23-M1 proteins. RESULTS:Significant cell death started at ATO concentrations above 2μmol/L.The growth and adhesion potential of H22 cells was inhibited in a time-and dose- dependent manner,and the migration and invasion potential of H22 cells was inhibited in a dose-dependent manner while ATO concentration was below 2μmol/L. Mice injected with ATO at a dose of 0.5 mg/kg had fewer lung metastases.However,mice injected with ATO at a dose of 2 mg/kg or 4 mg/kg had a high mortality rate and more liver injuries.A total of 15 different protein peaks were identified between the lysate of H22 cells treated with ATO and controls.Two proteins that peaked atm/z 5302 and 17207 coincided with MMP-2(fragment) and nm23-M1,respectively.Western blotting analyses demonstrated that MMP-2 and MMP-2 fragments were down-regulated and nm23-M1 was up-regulated in H22 cells treated with 2μmol/L ATO for 48 hours. CONCLUSIONS:ATO at a low dose inhibits the metastatic potential of mouse hepatoma H22 cells in vitro and in vivo, and involves down-regulation of MMP-2 and up-regulation of nm23-M1.展开更多
文摘Androgens play a central role in prostate cancer pathogenesis, and hence most of the patients respond to androgen deprivation therapies. However, patients tend to relapse with aggressive prostate cancer, which has been termed as hormone refractory. To identify the proteins that mediate progression to the hormone-refractory state, we used protein-chip technology for mass profiling of patients＇ sera. This study included 16 patients with metastatic hormone-refractory prostate cancer who were initially treated with androgen deprivation therapy. Serum samples were collected from each patient at five time points： point A, pre-treatment; point B, at the nadir of the prostate- specific antigen （PSA） level; point C, PSA failure; point D, the early hormone-refractory phase; and point E, the late hormone-refractory phase. Using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, we performed protein mass profiling of the patients＇ sera and identified a 6 640-Da peak that increased with disease progression. Target proteins were partially purified, and by amino acid sequencing the peak was identified as a fragment of apolipoprotein C-I （ApoC-I）. Serum ApoC-I protein levels increased with disease progression. On immunohistochemical analysis, the ApoC-i protein was found localized to the cytoplasm of the hormone-refractory cancer cells. In this study, we showed an increase in serum ApoC-I protein levels in prostate cancer patients during their progression to the hormone-refractory state, which suggests that ApoC-I protein is related to progression of prostate cancer. However, as the exact role of ApoC-I in prostate cancer pathogenesis is unclear, further research is required.
基金This study was supported by the grants from Beijing Municipal Science ＆ Technology Commission （No.H030930040230） and the National Natural Science Foundation of China （No.30772319）.
文摘Background Endometriosis is a common gynecological disease. This study aimed to screen proteins that were expressed differently in patients with endometriosis versus normal controls using proteomic techniques, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry （SELDI-TOF-MS）.Methods Protein chip SELDI-TOF-MS combines the advantages of microarray and mass spectrometry, and can screen latent markers in sera of patients with endometriosis. Serum samples from patients and normal volunteers were analyzed by SELDI-TOF-MS. Results After comparing the serum protein spectra of 36 patients with 24 normal controls, 24 differently expressed potential biomarkers （P 〈0.01） were identified. Using Biomarker Pattern software, we established a tree model of the 60 serum protein spectra. When using the three bJomarkers to classify the samples, the sensitivity for diagnosing endometriosis was 91.7%, specificity was 95.8%, and coincidence rate was 93.3%. Then we used serum samples from 12 patients and 8 normal controls to validate the tree model and report the sensitivity for diagnosing endometriosis was 91.7%, specificity was 75%, and coincidence rate was 85%. Conclusions SELDI-TOF-MS may be a useful tool in high-risk population screening for endometriosis. The identification and application of the biomarkers need to further study.
基金Supported by The National Science and Technology Pillar Program of the Ministry of Science and Technology of the People’s Republic of China during the Eleventh Five-Year plan period,No. 2007BAID4B02
文摘AIM:To investigate the relationship between urinary peptide changes and Helicobacter pylori(H.pylori) infection using urinary peptidome profiling.METHODS:The study was performed in volunteers(n = 137) who gave informed consent.Urinary peptides were enriched by magnetic beads based weak cation exchange chromatography and spectrums acquired by matrix-assisted laser desorption/ionization time-of-flight(MALDI-TOF) mass spectrometry(MS).ClinProTools bioinformatics software was used for statistical analysis and the recognition of peptide patterns.The marker peptides were identified by LTQ Obitrap XL tandem MS.RESULTS:Approximately 50 proteins or peptides which loaded onto the magnetic beads were detected by MALDI-TOF MS.By optimizing the parameters of the model,the Genetic Algorithm model had good recognition capability(97%) and positive predictive value(94%).Based on the model,2 markers with molecular masses of 6788 and 1912 Da were found that differentiated between H.pylori positive and negative volunteers.The m/z 1912 sequence was parsed as SKQFTSSTSYNRGDSTF.The peptide was identified as isoform 1 of the fibrinogen α chain precursor,whose concentration in urine was markedly higher in H.pylori infected volunteers than in H.pylori non-infected ones.CONCLUSION:The appearance of urinary fibrinogen degradation products is caused by an active H.pyloriinduced process.
文摘BACKGROUND:It has been pointed out that only low-dose arsenic trioxide(ATO)presents therapeutic benefits outweighing the toxic side effects.Low-dose ATO can effectively alleviate acute promyelocytic leukemia(APL). However,it is quite challenging in treating solid tumors. The purpose of this study was to investigate the effect of ATO at low concentrations on the metastatic potential of mouse hepatoma H22 cells and the anti-metastatic mechanism of ATO. METHODS:The metastatic potential of H22 cells was evaluated by adhesion,migration and invasion assays after exposure to a low dose of ATO in vitro.The mouse lung metastatic model induced by injection of H22 cells via the tail vein was adopted for the evaluation of metastatic potential. Different proteins in the lysate of H22 cells exposed to ATO at different concentrations were investigated by surface- enhanced laser desorption and ionization time-of-flight mass spectrometry(SELDI-TOF-MS).Finally,Western blotting analyses were made to detect the expression pattern of MMP-2 and nm23-M1 proteins. RESULTS:Significant cell death started at ATO concentrations above 2μmol/L.The growth and adhesion potential of H22 cells was inhibited in a time-and dose- dependent manner,and the migration and invasion potential of H22 cells was inhibited in a dose-dependent manner while ATO concentration was below 2μmol/L. Mice injected with ATO at a dose of 0.5 mg/kg had fewer lung metastases.However,mice injected with ATO at a dose of 2 mg/kg or 4 mg/kg had a high mortality rate and more liver injuries.A total of 15 different protein peaks were identified between the lysate of H22 cells treated with ATO and controls.Two proteins that peaked atm/z 5302 and 17207 coincided with MMP-2(fragment) and nm23-M1,respectively.Western blotting analyses demonstrated that MMP-2 and MMP-2 fragments were down-regulated and nm23-M1 was up-regulated in H22 cells treated with 2μmol/L ATO for 48 hours. CONCLUSIONS:ATO at a low dose inhibits the metastatic potential of mouse hepatoma H22 cells in vitro and in vivo, and involves down-regulation of MMP-2 and up-regulation of nm23-M1.
